Rep. Rick W. Allen Sells Abbott Laboratories (NYSE:ABT) Stock

Representative Rick W. Allen (Republican-Georgia) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on June 05th, the Representative disclosed that they had sold between $15,001 and $50,000 in Abbott Laboratories stock on April 16th. The trade occurred in the Representative’s “R.W. ALLEN & ASSOCIATES, INC. > RWA&A – SECURITIES” account.

Representative Rick W. Allen also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Intuit (NASDAQ:INTU) on 4/16/2026.
• Sold $15,001 – $50,000 in shares of Procter & Gamble (NYSE:PG) on 4/16/2026.
• Sold $15,001 – $50,000 in shares of S&P Global (NYSE:SPGI) on 4/16/2026.
• Sold $50,001 – $100,000 in shares of Ameriprise Financial (NYSE:AMP) on 4/15/2026.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $90.46 on Tuesday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm has a 50 day moving average price of $92.52 and a 200 day moving average price of $108.88. The company has a market cap of $157.57 billion, a price-to-earnings ratio of 25.34, a PEG ratio of 1.52 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Analyst Ratings Changes

ABT has been the subject of a number of research analyst reports. Oppenheimer dropped their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Royal Bank Of Canada lowered their target price on Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Citigroup dropped their price target on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Stifel Nicolaus reduced their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, The Goldman Sachs Group dropped their target price on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $119.09.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by company insiders.

Institutional Trading of Abbott Laboratories

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABT. Vanguard Group Inc. lifted its position in Abbott Laboratories by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. State Street Corp grew its holdings in shares of Abbott Laboratories by 2.1% during the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after acquiring an additional 1,627,791 shares in the last quarter. Capital International Investors boosted its position in Abbott Laboratories by 2.6% during the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock valued at $7,922,519,000 after purchasing an additional 1,614,706 shares during the last quarter. J. Stern & Co. LLP increased its position in Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares during the last quarter. Finally, Capital Research Global Investors raised its stake in shares of Abbott Laboratories by 1.0% during the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after purchasing an additional 400,400 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

About Representative Allen

Rick Allen (Republican Party) is a member of the U.S. House, representing Georgia’s 12th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Allen (Republican Party) ran for re-election to the U.S. House to represent Georgia’s 12th Congressional District. He won in the general election on November 5, 2024.

Allen was born in Augusta, Georgia, in 1951. He attended Auburn University in Alabama, graduating in 1973 with a B.S. in building construction.

After earning his degree, Allen worked as an estimator, project administrator and assistant to the president with a construction firm in Augusta. In 1976, he founded his own construction business, R. W. Allen & Associates, Inc. The company operates in six states across the country. In 2008, Allen was presented with the Augusta Metro Chamber of Commerce’s Small Business Person of the Year award.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.